mTOR as a target for cancer therapy.
The target of rapamycin, mTOR, acts as a sensor for mitogenic stimuli, such as insulin-like growth factors and cellular nutritional status, regulating cellular growth and division. As many tumors are driven by autocrine or paracrine growth through the type-I insulin-like growth factor receptor, mTOR is potentially an attractive target for molecular-targeted treatment. Further, a rationale for anticipating tumor-selective activity based on transforming events frequently identified in malignant disease is becoming established.
Houghton
P J
PJ
Department of Molecular Pharmacology, St. Jude Children's Research Hospital, 332 N. Lauderdale, Memphis, TN 38105-2794, USA. peter.houghton@stjude.org
Huang
S
S
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000037:antagonists & inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D002648:Child; D002986:Clinical Trials as Topic; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D011494:Protein Kinases / Q000378:metabolism*; D011972:Receptor, Insulin / Q000378:metabolism; D018232:Rhabdomyosarcoma, Alveolar / Q000188:drug therapy / Q000201:enzymology; D020123:Sirolimus / Q000037:antagonists & inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases; D014407:Tumor Cells, Cultured
D000903:Antibiotics, Antineoplastic; D007334:Insulin-Like Growth Factor I; D011494:Protein Kinases; C546842:MTOR protein, human; D011972:Receptor, Insulin; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus